吉西他滨联合卡铂治疗蒽环及紫杉类治疗失败的晚期乳腺癌的临床观察

Clinical observation of gemcitabme-carboplatm in the treatment of advanced breast cancer with anthracyclines and taxanes failure treatment

目的:探讨吉西他滨联合卡铂方案治疗蒽环及紫杉类治疗失败的晚期乳腺癌的疗效和不良反应。方法:将56例蒽环、紫杉类治疗失败的晚期乳腺癌患者随机分为观察组(30例)和对照组(26例)。观察组采用吉西他滨联合卡铂方案治疗,对照组采取CAF治疗方案。结果:治疗有效率观察组和对照组分别为73.33%和46.15%,观察组疗效显著优于对照组;不良反应的发生率两组之间没有明显差异。GC组及CAF组的中位肿瘤进展时间(TTP)分别为7.5个月和4.5个月,中位生存期分别为8.3个月和6.5个月,均无显著性差异(P>0.05)。结论:吉西他滨联合卡铂治疗蒽环及紫杉类治疗失败的晚期乳腺癌,具有很好的疗效和较低的毒副作用。

Objective： To investigate clinical effect and toxicity of gemcitabine - carboplatin in the treatment of advanced breast cancer with anthracyclines and taxanes treatment failure. Methods：All 56 cases of advanced breast cancer with anthracyelines and taxanes treatment failure were randomly divided into the observation group（30 cases） and control group （26 cases ）. The observation group received gemcitabine - carboplatin treatment and the control group received classic CAF treatment. Results ： The effective rates of the observation group and the control group were 73.33% and 46.15%. The curative effect of the observation group was significantly better than that of the control group. There was no difference in the incidence of adverse reactions between the two groups. The median time to progression（TTP） were 7.5 months and 4.5 months for the patients treated with GC and CAF respectively. The median survival time were 8.3 months,6.5 months in GC group and CAF group. There was no significant difference between them（P 〉 0.05 ）. Conclusion： Gemcitabine -carboplatin in the treatment of advanced bresst cancer with anthracyclines and taxanes treatment failure cancer has good efficacy and low toxicities.